Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
The company is based around the research on the skin microbiome by chief executive Dr Cath O’Neill and her team at Manchester University.
Berenberg’s share price target moves to £18.85 from £18.50, prompting a recommendation upgrade to ‘buy’ from ‘hold’.
In the six months ended March, revenues increased 31% to £2mln
Arix isn’t a fund and it certainly isn’t a traditional VC, although in a lot of ways it operates like one.
The deals followed technical evaluations of the technology.
“Profitability is an important target that we believe is within our reach without sacrificing appropriate investments in innovation, enhancing infrastructure and commercial capabilities,” the company said in a statement published alongside its interim results.
The catalyst for the change is the likely delay to the introduction of a low-cost, copycat version of GlaxoSmithKline’s (LON:GSK) inhaled asthma drug, Advair, being developed by the company.
The Lancet Infectious Diseases carried results from the CoDIFy study
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.